Indeed, acting as a GSM-like agent, GLT-1 might prove to be beneficial for AD patients, reducing aggregation-prone Aβ42 specie (and likely Aβ43) as well as Aβ40. This evidence concerns the gene NOP53 and Alzheimer disease.